References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021 Jul;71(4):359]. CA A Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
- National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer, 2018. https://seer.cancer.gov/statfacts/html/lungb.html
- American Lung Association State of Lung Cancer. Racial and Ethnic Disparities. 2021. lung.org/research/state-of-lung-cancer/racial-and-ethnic-disparities
- Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi MC, Halm EA. Ethnic disparities in the treatment of stage I non-small cell lung cancer. Am J Respir Crit Care Med. 2005;171(10):1158–1163. doi:10.1164/rccm.200411-1475OC.
- Hardy D, Liu C-C, Xia R, Cormier JN, Chan W, White A, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer. 2009;115(10):2199–2211. doi:10.1002/cncr.24248.
- Ha SY, Choi S-J, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget. 2015;6(7):5465–5474. doi:10.18632/oncotarget.2925.
- Lythgoe MP, Krell J, Savage P, Prasad V. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020. Prostate Cancer Prostatic Dis. 2021;24(4):1208–1211. doi:10.1038/s41391-021-00361-0.
- Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870.
- Lythgoe MP, Krell J, Kenny L, Khaki AR. Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021. Ann Oncol. 2021;32(Supplement 2):S88. doi:10.1016/j.annonc.2021.03.171.
- Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.61.
- Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62. doi:10.1038/bjc.2013.721.